OraQuick

US HIV Rapid Test Kits Market - Focused Insights 2023-2028 - ResearchAndMarkets.com

Retrieved on: 
星期三, 五月 31, 2023
AIDS, Health, BioMérieux, Bio-Rad Laboratories, Prevalence, HIV, Urine, OraSure Technologies, Abbott, Antibody, Sale, Blood, IVD, Diagnosis, Laboratory, OraQuick, Saliva, Vaccine, Pharmaceutical industry, Individual

This report offers market size & forecast data for HIV rapid test kits market in the US.

Key Points: 
  • This report offers market size & forecast data for HIV rapid test kits market in the US.
  • The revenue generated from the sale of HIV rapid test kits, which are a type of self-test kits and HIV rapid test kits purchased by individuals who can perform HIV rapid tests at home alone, are included in the report.
  • This report provides a comprehensive and current market scenario of the US HIV rapid test kits, including the US HIV rapid test kits market size, anticipated market forecast, relevant market segmentations, and industry trends.
  • The study considers a detailed scenario of the present HIV rapid test kits market and its market dynamics for 2023-2028 in the US.

APAC HIV Rapid Test Kits Market Report 2023: Sector to Reach $487.7 Billion in 2028 at a CAGR of 2.57% - ResearchAndMarkets.com

Retrieved on: 
星期二, 三月 28, 2023
AIDS, Health, BioMérieux, Bio-Rad Laboratories, Prevalence, HIV, Urine, OraSure Technologies, Abbott, Antibody, Sale, Blood, IVD, Laboratory, OraQuick, Saliva, Pharmaceutical industry, Vaccine, Video game

This report offers market size & forecast data for HIV rapid test kits market in APAC region.

Key Points: 
  • This report offers market size & forecast data for HIV rapid test kits market in APAC region.
  • The revenue generated from the sale of HIV rapid test kits which are a type of self-test kits and HIV rapid test kits purchased by individuals who can perform HIV rapid tests at home alone are includes in the report.
  • This report provides a comprehensive and current market scenario of the APAC HIV rapid test kits, including the APAC HIV rapid test kits market size, anticipated market forecast, relevant market segmentations, and industry trends.
  • The study considers a detailed scenario of the present HIV rapid test kits market and its market dynamics for 2023?2028 in APAC.

HIV Rapid Test Kits Market Report 2023-2028: Increasing HIV Self-Testing Associated Government Policies Bolsters Growth - ResearchAndMarkets.com

Retrieved on: 
星期二, 二月 14, 2023
Infectious Diseases, Health, Medical Devices, Organization, OraQuick, HIV, Viral, Government, Blood, OraSure Technologies, United Nations, HIV/AIDS, Developed country, Saliva, Patient, Eastern, Lancet, WHO, Power-on self-test, Death, Immune system, Knowledge, Plasma, Joint, Antibody, Disease, DBS, Serum, Joint United Nations Programme on HIV/AIDS, Infection, AIDS, Prevalence, Diagnosis of HIV/AIDS, COVID-19, UNAIDS, Pharmaceutical industry, Vaccine, Central Europe

The global HIV rapid test kits market size is expected to grow at a CAGR of 2.70% during 2022 to 2028.

Key Points: 
  • The global HIV rapid test kits market size is expected to grow at a CAGR of 2.70% during 2022 to 2028.
  • These steps lead to an increase in demand for HIVST that directly impact the HIV rapid test kits market.
  • The application of digital tools in HIV management is increasing that expected to fuel the HIV rapid test kits market.
  • The increasing access to HIV rapid test kits through health authorities and vendor activities and the acceptance of self-testing kits for HIV management are increasing simultaneously, fueling the HIV rapid test kits market growth.

OraSure Technologies Continues its Dedication to Ending the HIV Epidemic

Retrieved on: 
星期四, 十二月 1, 2022
CDC, HIV-2, Risk, Regulation of tobacco by the U.S. Food and Drug Administration, AIDS, HIV, Infection, Algorithm, Privacy, WHO, OTC, Korea Disease Control and Prevention Agency, Disagreement, HIV-1, U.S. government and smoking cessation, Informatics, Health, Uncertainty, Coronavirus, FDA, COVID-19, COVID-19 testing, Government, Public health, Food, Hospital, Partnership, OraQuick, Pre-exposure prophylaxis, Annual report, OraSure Technologies, Disease, World Health Organization, Patent, Pharmacy, Research, Antibody, Viral load, Seroconversion, Centers for Disease Control and Prevention timeline, World AIDS Day, Sale, Intellectual property, Collection, Pharmaceutical industry, Vaccine, Risk management

OraSure has played a critical role in the fight against HIV globally since 2002.

Key Points: 
  • OraSure has played a critical role in the fight against HIV globally since 2002.
  • In 2012, the Company received FDA approval for the first, and still only, over-the-counter oral fluid HIV test, the OraQuick In-Home HIV Test.
  • The OraQuick In-Home HIV Test is the first and only oral fluid rapid over-the-counter (OTC) HIV test approved in the U.S.
  • The forward-looking statements are made as of the date of this press release and OraSure Technologies undertakes no duty to update these statements.

OraSure Wins Contract to Supply “Together Take Me Home,” HIV Self-Testing Initiative Sponsored by the Centers for Disease Control and Prevention

Retrieved on: 
星期二, 九月 20, 2022
Emory, Health, Government, Algorithm, Center, COVID-19, Infection, Risk, FDA, HIV-2, Food, Sale, OraSure Technologies, Emory University, HIV, Privacy, Antibody, Company, Intellectual property, HIV/AIDS denialism, HIV-1, Diagnosis of HIV/AIDS, Forward-looking statement, Program, Patient, Regulation of tobacco by the U.S. Food and Drug Administration, OTC, Technology, Public health, CDC, Solution, Uncertainty, Annual report, Coronavirus, OraQuick, NASDAQ, Korea Disease Control and Prevention Agency, Collection, WHO, Research, Pharmacy, GLOBE, COVID-19 testing, SEC, Awareness, Centers for Disease Control and Prevention timeline, Hospital, Patent, Disagreement, Informatics, Vaccine, Pharmaceutical industry, Diagnosis

This program follows a successful collaborative pilot program by the same name, for which OraSure also supplied tests.

Key Points: 
  • This program follows a successful collaborative pilot program by the same name, for which OraSure also supplied tests.
  • As part of the program, OraSure will provide up to one million OraQuick In-Home HIV tests over a five- year period.
  • The program will target populations that are disproportionately affected by HIV and less likely to have access to key prevention services.
  • The OraQuick In-Home HIV Test is the first and only oral fluid rapid over-the-counter (OTC) HIV test approved in the U.S.

OraSure Technologies, Inc. Expands HIV Oral Swab In-home Test into Europe

Retrieved on: 
星期二, 一月 25, 2022
Food, Center, OraSure Technologies, OraQuick, Solution, HIV-2, COVID-19 testing, HIV/AIDS denialism, Coronavirus, Collection, Forward-looking statement, COVID-19, Intellectual property, SEC, Prevalence, Therapy, Risk, Research, Health, Technology, Algorithm, NASDAQ, Disagreement, Government, Uncertainty, Company, Annual report, Antibody, Hospital, Pharmacy, Regulation of tobacco by the U.S. Food and Drug Administration, Public health, MBA, Education, MD, HIV, GLOBE, Informatics, HIV-1, Korea Disease Control and Prevention Agency, Patent, Pharmaceutical industry, Vaccine

Were now expanding into European countries to give people there more choice and access to HIV self testing.

Key Points: 
  • Were now expanding into European countries to give people there more choice and access to HIV self testing.
  • OraQuick is the worlds first in-home oral HIV Test.
  • It is a CE-marked, pain-free HIV test that is simple to use, requiring a swipe of the upper gum and lower gum which collects HIV antibodies in oral fluid.
  • The OraQuick HIV Self-Test uses these non-infectious HIV antibodies to detect the presence of HIV.